Santa Clara Law Digital Commons
metadata only
Cheap Drugs at What Price to Innovation: Does the Compulsory Licensing of Pharmaceuticals Hurt Innovaton?
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Rethinking Mandated Drug Treatment: Why Expanding Freedom Requires Structural Drug Policy Reform.#159615
- The International Conference on Harmonization of Pharmaceutical Regulations, the European Medicines Evaluation Agency, and the FDA: Who's Zooming Who?#493910
- Propuesta de innovación Plan Institucional LEO para fortalecer la competencia lectora de estudiantes del nivel primaria#1081688
- Tracking Global Compulsory Licensing Trends in Biopharmaceuticals#391083
- Mind the Gap: Challenges Moving Trial Doses Into Practice#268816
Record · ID 648157
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive